Advanced search
Publication Cover
Future Medicinal Chemistry Volume 16, 2024 - Issue 9: Future Medicinal Chemistry
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2

Yong Yan1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaView further author information
,
Hanwen Liu1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaView further author information
,
Di Wu1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaView further author information
,
Zhihao Gu1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China;2 Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, ChinaView further author information
,
Wenhao Guo1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaView further author information
,
Hequan Yao1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaORCID Iconhttps://orcid.org/0000-0003-4865-820XView further author information
ORCID Icon,
Kejiang Lin1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6351-5683View further author information
ORCID Icon &
Xuanyi Li1 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4367-3005View further author information
ORCID Icon show all
Pages 887-903 | Received 12 Jan 2024, Accepted 15 Mar 2024, Published online: 15 Apr 2024

References

  • Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382(8), 727–733 (2020).
  • Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8(5), 475–481 (2020).
  • Wu F, Zhao S, Yu B et al. A new coronavirus associated with human respiratory disease in China. Nature 579(7798), 265–269 (2020).
  • Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19(3), 141–154 (2020).
  • Zhou P, Yang X-L, Wang X-G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270–273 (2020).
  • Hegyi A, Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 83(3), 595–599 (2002).
  • Xiong M, Su H, Zhao W, Xie H, Shao Q, Xu Y. What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design. Med. Res. Rev. 41(4), 1965–1998 (2021).
  • Jin Z, Du X, Xu Y et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7811), 289–293 (2020).
  • Yang H, Yang M, Ding Y et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100(23), 13190–13195 (2003).
  • Fan K, Ma L, Han X et al. The substrate specificity of SARS coronavirus 3C-like proteinase. Biochem. Biophys. Res. Commun. 329(3), 934–940 (2005).
  • Galasiti Kankanamalage AC, Kim Y, Damalanka VC et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur. J. Med. Chem. 150, 334–346 (2018).
  • Bjorkman P, Yang H, Xie W et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLOS Biol. 3(10) (2005).
  • Hattori S-I, Higashi-Kuwata N, Hayashi H et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 12(1) (2021).
  • Zhang K, Wang T, Li M et al. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). Eur. J. Med. Chem. 257, 115487 (2023).
  • Citarella A, Scala A, Piperno A, Micale N. SARS-CoV-2 Mpro: a potential target for peptidomimetics and small-molecule inhibitors. Biomolecules 11(4) (2021).
  • Drayman N, Demarco JK, Jones KA et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science 373(6557), 931–936 (2021).
  • Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. Coronaviruses – drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15(5), 327–347 (2016).
  • Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med. Chem. 59(14), 6595–6628 (2016).
  • La Monica G, Bono A, Lauria A, Martorana A. Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives. J. Med. Chem. 65(19), 12500–12534 (2022).
  • Owen DR, Allerton CMN, Anderson AS et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374(6575), 1586–1593 (2021).
  • Su H, Yao S, Zhao W et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat. Commun. 12(1) (2021).
  • Dai W, Zhang B, Jiang X-M et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368(6497), 1331–1335 (2020).
  • Qiao J, Li Y-S, Zeng R et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science 371(6536), 1374–1378 (2021).
  • Sacco MD, Ma C, Lagarias P et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci. Adv. 6(50), eabe0751 (2020).
  • Huang Q, Quan B, Chen Y et al. Discovery of alpha-ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups. Bioorg. Chem. 143, 107001 (2024).
  • Zhang H, Zhou K, Peng F et al. Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency. J. Infect. 88(2), 211–214 (2024).
  • Unoh Y, Uehara S, Nakahara K et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65(9), 6499–6512 (2022).
  • Jiang Z, Feng B, Zhang Y et al. Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment. Signal Transduct. Target. Ther. 8(1) (2023).
  • Su H-X, Yao S, Zhao W-F et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol. Sin. 41(9), 1167–1177 (2020).
  • Kitamura N, Sacco MD, Ma C et al. Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors. J. Med. Chem. 65(4), 2848–2865 (2021).
  • Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs 82(5), 585–591 (2022).
  • Marzolini C, Kuritzkes DR, Marra F et al. Recommendations for the management of drug–drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications. Clin. Pharmacol. Ther. 112(6), 1191–1200 (2022).
  • Sindelar M, McCabe D, Carroll E. Tacrolimus drug–drug interaction with nirmatrelvir/ritonavir (Paxlovid™) managed with phenytoin. J. Med. Toxicol. 19(1), 45–48 (2022).
  • Yang H, You M, Shu X et al. Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2. Eur. J. Med. Chem. 257, 115512 (2023).
  • Mukae H, Yotsuyanagi H, Ohmagari N et al. A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob. Agents Chemother. 66(10), e00697–00622 (2022).
  • Zhang C-H, Stone EA, Deshmukh M et al. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent. Sci. 7(3), 467–475 (2021).
  • Kneller DW, Li H, Galanie S et al. Structural, electronic, and electrostatic determinants for inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease. J. Med. Chem. 64(23), 17366–17383 (2021).
  • Han SH, Goins CM, Arya T et al. Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro). J. Med. Chem. 65(4), 2880–2904 (2021).
  • Ma C, Xia Z, Sacco MD et al. Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity. J. Am. Chem. Soc. 143(49), 20697–20709 (2021).
  • Huang Z, Yu X, Huang X. α-Hypervalent iodine functionalized phosphonium and arsonium ylides and their tandem reaction as umpolung reagents. J. Org. Chem. 67(23), 8261–8264 (2002).
  • Ma L, Pei H, Lei L et al. Structural exploration, synthesis and pharmacological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives as iNOS inhibitors against inflammatory diseases. Eur. J. Med. Chem. 92, 178–190 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.